Meanwhile, sorafenib resistance of HepG2-SR cells were closely linked to LDs formation and reversed by the knockdown of ING5 or lipogenic enzymes (ACC1 and ACLY) inhibitor, indicating that ING5 may promote lipogenesis and subsequently facilitate sorafenib resistance of HCC cells. The gene discussed is ACLY; the disease is hepatocellular carcinoma.